

# Minh Patrick LÃ<sup>a</sup>

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4631649/publications.pdf>

Version: 2024-02-01

36  
papers

446  
citations

933447

10  
h-index

752698

20  
g-index

36  
all docs

36  
docs citations

36  
times ranked

846  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2016, 65, 40-47.	3.7	161
2	Prediction of human fetal pharmacokinetics using <i>ex vivo</i> human placenta perfusion studies and physiologically based models. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 646-657.	2.4	64
3	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2376-2380.	3.0	25
4	Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	21
5	Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model. <i>Aids</i> , 2020, 34, 2145-2149.	2.2	17
6	Plasma concentrations of atovaquone given to immunocompromised patients to prevent <i>Pneumocystis jirovecii</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2602-2606.	3.0	14
7	Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19. <i>Journal of Infection</i> , 2021, 82, 159-198.	3.3	14
8	Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2657-2660.	3.0	13
9	Placental transfer of Letemovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection. <i>PLoS ONE</i> , 2020, 15, e0232140.	2.5	13
10	Pharmacokinetics, Safety and Efficacy of Ritonavir-Boosted Atazanavir (300/100 mg Once Daily) in HIV-1-Infected Pregnant Women. <i>Antiviral Therapy</i> , 2015, 20, 507-513.	1.0	11
11	Placental transfer of elvitegravir and cobicistat in an ex-vivo human cotyledon double perfusion model. <i>Aids</i> , 2018, 32, 321-325.	2.2	10
12	Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1517-1521.	3.0	9
13	Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3167-3171.	3.0	8
14	Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1992-2002.	3.0	8
15	Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2120-2128.	3.0	7
16	Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 473-481.	1.9	6
17	Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	6
18	Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2404-2413.	2.4	6

#	ARTICLE	IF	CITATIONS
19	Placental transfer of doravirine, a recent HIV-1 NNRTI in the <i>ex vivo</i> human cotyledon perfusion model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2364-2367.	3.0	6
20	Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS 163 ETRAL Study. <i>Pharmacotherapy</i> , 2019, 39, 514-520.	2.6	4
21	Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2706-2707.	3.0	4
22	Identifying lithium-poisoned patients who may benefit from haemodialysis remains highly challenging. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2542-2543.	2.4	4
23	Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study: Figure 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2418-2420.	3.0	3
24	Reply to Yan and Muller, "Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity". <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	3
25	Bictegravir pharmacokinetics in a late-presenting HIV-1-infected pregnant woman: a case report. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 851-853.	3.0	3
26	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 277-279.	3.0	2
27	Reply to: "Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease". <i>Journal of Hepatology</i> , 2016, 65, 1065-1066.	3.7	1
28	Once-daily darunavir/ritonavir 400/100mg in triple therapy: efficacy and penetration in seminal compartment in ANRS 165 DARULIGHT study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 277-280.	2.4	1
29	Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1893-1897.	3.0	1
30	A case of tuberculosis and black-grain eumycetoma co-infection in a non-endemic country: clinical presentation and therapeutic management. <i>International Journal of Infectious Diseases</i> , 2021, 112, 186-188.	3.3	1
31	Title is missing!. , 2020, 15, e0232140.		0
32	Title is missing!. , 2020, 15, e0232140.		0
33	Title is missing!. , 2020, 15, e0232140.		0
34	Title is missing!. , 2020, 15, e0232140.		0
35	Title is missing!. , 2020, 15, e0232140.		0
36	Title is missing!. , 2020, 15, e0232140.		0